S34-1035
S34-1035 is a selective AKR1C3 inhibitor with an IC50 of 0.04 μM. As a chemosensitizer, S34-1035 restores the sensitivity of doxorubicin-resistant breast cancer cells to doxorubicin. S34-1035 can be used in breast cancer research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3099381-65-1
- Fòrmula: C17H15N3O2
- Peso molecular:293.32
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas 17β-HSD
More
Actividad biológica
S34-1035 potently and selectively inhibits purified recombinant AKR1C3 with an IC50 of 0.04 μM, exhibiting over 2500-fold selectivity over AKR1C1, AKR1C2, and AKR1C4[1].
S34-1035 (0-100 μM; 72-96 h) exhibits weak antiproliferative activity against MCF-7/DOX cells alone, with the cell survival rate remaining above 70% after treatment with 100 μM for 96 h[1].
S34-1035 (10-50 μM; 24 h pretreatment, 72 h co-treatment) exerts strong synergistic effects with Doxorubicin (HY-15142A) to reduce the viability of MCF-7/DOX cells, with a combination index (CI) value ranging from 0.145 to 0.637, while it shows no single-agent cytotoxicity at the tested concentrations[1].
Combination treatment with S34-1035 (10 μM; 14 days) and Doxorubicin completely inhibits the colony-forming ability of MCF-7/DOX cells, whereas S34-1035 alone has no effect on colony formation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:doxorubicin-resistant MCF-7/DOX breast cancer cells
-
Concentration:0, 5, 10, 25, 40, 60, 80, 100 μM
-
Incubation Time:72 h; 96 h
-
Result:Showed weak antiproliferative activity even at the highest tested concentration of 100 μM, with cell viability remaining above 70% after 96 h of treatment, indicating good cellular safety.
-
Cell Line:doxorubicin-resistant MCF-7/DOX breast cancer cells
-
Concentration:0, 10, 25, 50 μM (S34-1035); 0, 10, 25, 50 μM (Doxorubicin)
-
Incubation Time:24 h pretreatment; 72 h co-treatment
-
Result:Produced significantly stronger antiproliferative effects than Doxorubicin alone across all tested concentrations.
Showed combination index (CI) values ranging from 0.145 to 0.637, indicating strong to very strong synergy.
Showed no measurable inhibitory effect on cell viability at tested concentrations when used alone.
Chemical Information
-
No. CAS 3099381-65-1
-
Peso molecular 293.32
-
Fòrmula C17H15N3O2
-
SMILES
N#CC1=CC=C(C=C1)CNC(C2=CC(C(C3CC3)=O)=CN2)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
S34-1035 Related Classifications
HY-184927 Related Classifications
Powered by Bioz